Scalable End-to-End Clinical Pharmacovigilance for a Resource-Constrained Biotech
As clinical development programs expand, biotechnology companies often face increasing pharmacovigilance (PV) demands while operating with limited internal resources. For one biotech company managing a growing global oncology portfolio, rising operational complexity, evolving regulatory requirements, and the absence of internal PV expertise created the need for a scalable, fully managed solution.
To address these challenges, the company partnered with Qinecsa to implement a comprehensive, end-to-end clinical pharmacovigilance model. Acting as a single accountable partner, Qinecsa provided both operational delivery and strategic PV leadership across the client’s clinical development portfolio.
The Challenge: Managing Global PV Without an Internal Team
The client’s oncology portfolio was growing, with multiple studies progressing through different stages of development. This created increasing operational and regulatory complexity across global regions. At the same time, budget constraints required a cost-efficient delivery model capable of supporting current and future needs.
Reducing Complexity and Vendor Fragmentation
The organization wanted to simplify its pharmacovigilance operating model by reducing the need to manage multiple vendors. It required a trusted partner capable of overseeing all PV activities, ensuring global compliance, and providing the expertise typically expected from an in-house pharmacovigilance function.
The Solution: A Single-Vendor End-to-End PV Model
Beginning in December 2023, Qinecsa implemented a fully integrated Clinical Pharmacovigilance Services model that covered all studies within the client’s portfolio. The approach provided a centralized framework for managing safety activities while enabling flexibility as development programs expanded.
Comprehensive Pharmacovigilance Support
Services delivered by Qinecsa included:
- SAE management
- SAE reconciliation
- Regulatory submissions
- Reference Safety Information (RSI) management
- Signal and risk management
- Aggregate reporting
- Trusted Deputy support
This end-to-end model ensured consistency across safety activities and provided a single point of accountability for global PV operations.
Acting as an Embedded PV Function
Beyond operational delivery, Qinecsa served as an embedded strategic partner. Ongoing guidance and oversight helped the client navigate pharmacovigilance requirements across regions, effectively providing the capabilities of an internal PV department without the need to build one in-house.
As the client’s needs evolved, Qinecsa scaled delivery to support three additional studies, demonstrating the flexibility of the model.
The Outcome: Reliable Performance and Scalable Growth
The partnership delivered measurable operational success. Qinecsa achieved 100% SLA performance across all KPIs, exceeding agreed thresholds and supporting consistent delivery across the client’s portfolio.
The client benefited from seamless global pharmacovigilance operations, reduced internal burden, and a scalable model capable of supporting ongoing portfolio growth. Without an internal PV team, the organization gained access to both operational expertise and strategic guidance through a single accountable partner.